Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

CATL Sets Up Subsidiary to Take Advantage of China’s Push to Electrify Ships
CATL Sets Up Subsidiary to Take Advantage of China’s Push to Electrify Ships
XPeng Warns of Quarterly Sales Crash as Losses Widen
Meituan Posts Surprise Profit Soon After Tencent Announces Exit
Chipmaker Gets Go Ahead for $1.7 Billion Shanghai IPO
Bosch Opens Shanghai R&D Center to Take On Chinese Heavyweights in Autonomous Driving
TuSimple Tells SEC It Can’t Report Earnings on Time
Top Tencent Investor Naspers Considers Selling Meituan Shares
Chinese EV Startup Cuts Salaries Amid Ballooning Losses, Sources Say
Tencent Wins New Game License After 17-Month Drought
Former TuSimple Chairman Retakes the Wheel After Leadership Reshuffle
Tencent to Give $20 Billion Meituan Stake to Shareholders
In Depth: Rival Ride-Hailing Apps Challenge Didi in World’s Biggest Market
Tesla Cooperating With Investigators After Fatal Runaway Car Crash
China’s 5G Services Need an Upgrade as Popularity Slips, Ericsson Exec Says
Analysis: Will Nvidia’s Custom-Made New Chip for China Work?
COMAC Secures 300 More Orders for Homegrown C919 Jets
China’s Lepu Scientech Makes Muted Hong Kong Debut
AI Startup Xiaoice Raises $138.4 Million in Third-Round Funding
Chinese Chip-Wafer Maker Hua Hong Files for $2.5 Billion Shanghai IPO
China Chip Gear Ban May Whack $2.5 Billion Off Lam’s Revenue
Market Rattled by Kangmei’s $4.4 Billion Accounting Error

By Wang Juanjuan and Han Wei / May 01, 2019 12:37 AM / Finance

Photo: VCG

Photo: VCG

Shares and bonds of one of China’s largest listed drugmakers tumbled Tuesday after the company restated 29.9 billion yuan ($4.4 billion) of 2017 results, fueling suspicions of fraud.

Shanghai-listed Kangmei Pharmaceutical Co. Ltd., a producer of traditional Chinese medicines, said in a filing that there were multiple “accounting errors” in its 2017 results, leading to 29.9 billion yuan overstatement of the company’s cash holding. Late last year, Kangmei said it was investigated by securities regulators for suspected violations of information disclosure rules.

Kangmei’s stock, a component of MSCI Inc.’s global indexes, slumped by the 10% daily limit. The company’s bonds fell by 20%.

Several audit professionals said they were concerned that there may be problems in Kangmei’s financials beyond accounting errors, given the vague language and lack of logic in its correction statement. They said they suspected the company may have intentionally inflated its cash holding and inventories to boost profit.

Guangfa Securities and GP Certified Public Accountants Co. Ltd. have served in Kangmei’s financial and accounting operations.

Kangmei was involved in several bribery cases involving government officials. According to court documents released last June, the company bribed Cai Ming, former director of the drug safety supervision department at the Guangdong Province Food and Drug Administration, to the tune of 300,000 yuan from 2014 to 2015.

In February, the company was rattled by default risks on $300 million of bonds. The crisis was eased later after the Guangdong provincial government stepped in.

This story has been updated to correct the year of Kangmei’s financial report that contained errors. The report was for the year 2017, and it contained multiple errors.

Related: Pharmaceutical Firm Avoids Default as Guangdong Pressures Customers

Share this article
Open WeChat and scan the QR code